Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>On August 12, 2024, Satellos Bioscience Inc. (MSCLF) announced financial results for the second quarter of 2024 and provided a business update.</li><li> The company announced new data from a canine model of Duchenne muscular dystrophy (DMD) that showed treatment with SAT-3247 led to an increase in Regeneration Index, which measures the number of newly regenerated muscle fibers compared to the number of damaged and dying muscle fibers.</li><li> Satellos also recently announced the acceptance of a regulatory filing to commence a Phase 1 clinical trial of SAT-3247.</li></ul>

On August 12, 2024, Satellos Bioscience Inc. (MSCLF) announced financial results for the second quarter of 2024 and provided a business update. The company announced new data from a canine model of Duchenne muscular dystrophy (DMD) that showed treatment with SAT-3247 led to an increase in Regeneration Index, which measures the number of newly regenerated muscle fibers compared to the number of damaged and dying muscle fibers. Satellos also recently announced the acceptance of a regulatory filing to commence a Phase 1 clinical trial of SAT-3247.

MSCLF: SAT-3247 Enhances Muscle Repair in Canine Model of DMD 

<ul><li>On May 14, 2024, Satellos Biosciences Inc. (MSCLF) announced financial results for the first quarter of 2024 and provided a business update.</li><li>Satellos is on track to initiate a Phase 1 first-in-human clinical trial of its lead development asset SAT-3247 in mid-2024.</li><li>The company has completed manufacturing bulk quantities of the drug and formulated the first tablets for use in the trial.</li></ul>

On May 14, 2024, Satellos Biosciences Inc. (MSCLF) announced financial results for the first quarter of 2024 and provided a business update.Satellos is on track to initiate a Phase 1 first-in-human clinical trial of its lead development asset SAT-3247 in mid-2024.The company has completed manufacturing bulk quantities of the drug and formulated the first tablets for use in the trial.

MSCLF: On Track to Initiate Phase 1 First-in-Human Trials of SAT-3247 in mid-2024 

Canada

Satellos is a biotechnology company founded on game changing science in skeletal muscle regeneration. Our vision is to invent and develop medicines which reset the body's innate ability for self-repair as a truly novel approach for the treatment of devastating muscle disorders.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Satellos Bioscience (MSCLF US)

MSCLF: SAT-3247 Enhances Muscle Repair in Canine Model of DMD

On August 12, 2024, Satellos Bioscience Inc. (MSCLF) announced financial results for the second quarter of 2024 and provided a business update. ...

Zacks Small Cap Research

MSCLF: On Track to Initiate Phase 1 First-in-Human Trials of SAT-3247 in mid-2024

On May 14, 2024, Satellos Biosciences Inc. (MSCLF) announced financial results for the first quarter of 2024 and provided a business...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)